Drug Profile
Arginine butyrate
Alternative Names: HQK-1004Latest Information Update: 06 Aug 2015
Price :
$50
*
At a glance
- Originator Boston University
- Developer Boston University; HemaQuest Pharmaceuticals
- Class Basic amino acids; Butyrates; Diamino amino acids; Essential amino acids; Small molecules
- Mechanism of Action Thymidine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Epstein-Barr virus infections; Sickle cell anaemia; Thalassaemia
Most Recent Events
- 05 Jan 2011 Arginine butyrate is available for licensing as of 05 Jan 2011. http://www.hemaquest.com
- 05 Nov 2010 HemaQuest Pharmaceuticals terminates a phase II trial [NCT00992732] in EBV-positive lymphoid malignancies in USA
- 06 Jul 2010 HemaQuest Pharmaceuticals terminates a phase II trial [NCT00917826] in EBV-positive lymphoid malignancies in USA